Reversal of acquired osimertinib resistance by YAP inhibition in lung cancer is associated with lipid metabolic reprogramming.
Osimertinib (Osi), as the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC). However, recent studies have found that its acquired resistance severely limits its therapeutic effect. This stud...